Tyrus Capital S.A.M.’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Tyrus Capital S.A.M.’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-400,000	Closed	-$4.04M	–	45
2022 Q4	$4.04M	Buy	+400,000	New	+$4M	8.8%	5

Tyrus Capital S.A.M.'s EBAC Position: Q1 2023 in Review

Tyrus Capital S.A.M. sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 400,000 shares — an estimated $4.04M sold.

Tyrus Capital S.A.M. first reported a position in EBAC in Q4 2022 and held it in 1 quarter. The position peaked at $4.04M in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Tyrus Capital S.A.M. reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Tyrus Capital S.A.M. sold 400,000 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $4.04M.
Tyrus Capital S.A.M. first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q4 2022 and held it in 1 quarter.
Tyrus Capital S.A.M.'s European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $4.04M in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Tyrus Capital S.A.M.'s 13F filing for Q1 2023, filed 15 May 2023.